Alpha Cognition Inc. · NASDAQ:ACOG
Alpha Cognition — Investor Presentation (April 2022)
27 slides from Alpha Cognition's investor presentation, April 2022
Slide 1: Corporate Presentation
Corporate Presentation Bringing hope to people living with Alzheimer's Disease COPYRIGHT 2021 ALPHA COGNITION, INC.
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by Alpha Cognition Inc. (“ACI” or the “Company”). This presentation includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this present
Slide 3: Late-Stage Biopharmaceutical Company Focused On Neurodegenerative Diseases
Late-Stage Biopharmaceutical Company Focused On Neurodegenerative Diseases ALPHA-1062: patented potential New Chemical Entity for the treatment of mild-to-moderate Alzheimer’s Dementia • Potential best-in-class treatment designed to optimize efficacious dose, minimize treatment-limiting side-effects
Slide 4: Pipeline Programs
Pipeline Programs Phase 3 / Status / Indication Preclinical Phase 1 Phase 2 Pivotal Upcoming Milestones Alzheimer’s Dementia Pivotal Study Top-line Results Q2/22 ALPHA-1062 Pt Tolerability Study Starts Q2/22 Enteric-coated Tablet NDA filing Q3/22 ALPHA-1062 + Formulation development ongoing for Mema
Slide 5: Alzheimer's Disease Overview
Alzheimer’s Disease Overview Alzheimer’s Disease (AD) is a progressive neurodegenerative disease for which there is no cure AD is characterized by loss of cholinergic neurons in the brain Decreased acetylcholine levels and loss of receptors negatively impacts learning, memory and function AD Impacts
Slide 6: ALPHA-1062 Is A Pro-Drug of Galantamine With Decreased Side-Effects And Increased Bioavailability
ALPHA-1062 Is A Pro-Drug of Galantamine With Decreased Side-Effects And Increased Bioavailability The formation of the benzoyl ester eliminates AChE inhibition; the gluconate salt increases solubility ALPHA-1062 is absorbed in the small intestine as an inactive compound with minimal or no side effec
Slide 7: ACHEIs Activity In The GI Nervous System Overstimulates Local Neurons Resulting In Side-Effects
ACHEIs Activity In The GI Nervous System Overstimulates Local Neurons Resulting In Side-Effects INTESTINAL LUMEN AChEl absorbed in small intestine AChEl AChEl AChEl Binds to AChE, AChEl increases ACh levels and overstimulates ALPHA-1062 is local neurons absorbed as an AChEl inert drug No activity in
Slide 8: Galantamine Enhances Acetylcholine Levels And Nicotinic Receptor Sensitivity
Galantamine Enhances Acetylcholine Levels And Nicotinic Receptor Sensitivity Decreased acetylcholine levels and loss of nicotinic acetylcholine receptors (nAChR) negatively impacts learning, memory, and function B Current therapeutics1 increase acetylcholine levels by inhibiting acetylcholinesterase
Slide 9: Exploratory Studies Have De-risked Pivotal BA/BE Trial
Exploratory Studies Have De-risked Pivotal BA/BE Trial Bioequivalence Study Demonstrating 15% Parameters Required to Establish Superior Bioavailability Bioequivalence3,4 50 Razadyne IR 8mg Tablet2 ALPHA-1062 ALPHA-1062 RAZADYNE Pharmacokinetic 11 mg Enteric ALPHA-1062 SL 11mg* Tablet1 11 mg Sublingu
Slide 10: ALPHA-1062 Pivotal Bioavailability/Bioequivalence Study
ALPHA-1062 Pivotal Bioavailability/ Bioequivalence Study Screening 1st Dose 2nd Dose Bioanalysis Topline Data Study Report Food Effect Study 7-day Washout Data Analysis 2-months Screening Study Report 1st Dosing 2nd Dosing Bioanalysis Topline Data Fasted Study 7-day Washout Data Analysis 2-months St
Slide 11: Exploratory Studies Have Demonstrated Improved Gastrointestinal Side Effect Profile
Exploratory Studies Have Demonstrated Improved Gastrointestinal Side Effect Profile* No reported GI side-effects with oral formulations of ALPHA-1062 (Enteric Coated and Sublingual Tablets, n=30) Diarrhea Nausea & Vomiting 40 37.8 35 % of Subjects Reporting GI Episode 30 25 20.0 20 15 10 8 9 5 0 0 0
Slide 12: Long-Term Use Of Galantamine Is Associated With Delayed Placement In Long-Term Care
Long-Term Use Of Galantamine Is Associated With Delayed Placement In Long-Term Care 80% of galantamine-treated patients % Patients Living Outside of Nursing Home1 were living independently versus 100% 30% of untreated patients at 36 months1 90% 80% 80% 70% 60% Galantamine – 60% Treated 50% 40% 30% 3
Slide 13: Long-term Effects Of Cholinesterase Inhibitors On Mortality and Cognitive Decline
Long-term Effects Of Cholinesterase Inhibitors On Mortality and Cognitive Decline • In an April 2021 Neurology publication, 39,196 Alzheimer/Mixed Dementia patients (Swedish Dementia Registry) were evaluated between 2007-2017 with a 5yr average follow-up • Galantamine was associated with lower risk
Slide 14: ALPHA-1062 Offers Potential Best-In-Class Profile Versus Approved ACHEIs
ALPHA-1062 Offers Potential Best-In-Class Profile Versus Approved ACHEIs ALPHA-1062 Donepezil Galantamine Rivastigmine* Time to Faster onset of improvement when Symptomatic started at therapeutic dose Improvement Time to Initiate therapy at most efficacious dose Therapeutic Dose with low/no titratio
Slide 15: Market Research Confirms Alpha-1062 Key Attributes Provide A Strong Platform For A Unified Brand Story
Market Research Confirms Alpha-1062 Key Attributes Provide A Strong Platform For A Unified Brand Story HCP CAREGIVER PAYER 78% of HCPs likely 26%-41% 88% of Caregivers likely to to prescribe preference share request from HCP Low risk of dizziness and improved patient adherence key drivers of favorab
Slide 16: Multiple AD Launches Have Achieved Blockbuster Status
Multiple AD Launches Have Achieved Blockbuster Status COPYRIGHT 2021 ALPHA COGNITION, INC. Source – IQVIA National Sales Perspectives – 1993 through 2020. 16
Slide 17: ACHEIs Market Large but Dissatisfied Creating Opportunity For Improved Treatment Option
ACHEIs Market Large but Dissatisfied Creating Opportunity For Improved Treatment Option Prescriptions by Specialty 1 Percentage of Alzheimer’s Disease Treated Patients Reaching Each Line of Therapy 2 Neuro/ Psych LTC 27% 36% Other PCP 9% 28% • ACHEI Market • High discontinuation rates of current the
Slide 18: ALPHA-1062 AD Opportunity
ALPHA-1062 AD Opportunity De-risked Large but ALPHA-1062 Clinical Development Near-term Dissatisfied Market Potential Program Milestones $5B in sales Reduced GI Side- Single Pivotal Trial at branded price Effects Bioequivalence Underway and Study Low/No Titration Tolerability Trial required for NDA
Slide 19: ALPHA-1062 + Memantine Will Expand Usage Into Severe Alzheimer's Dementia
ALPHA-1062 + Memantine Will Expand Usage Into Severe Alzheimer’s Dementia Mild • Memantine indicated for moderate-to-severe Alzheimer’s dementia • Often used in combination with an ACHEI – 7.7 million Rx written for memantine- containing product1 – The majority of treated AD patients (56.5%) receive
Slide 20: Progranulin Offers Therapeutic Potential Across Neurodegenerative Diseases
Progranulin Offers Therapeutic Potential Across Neurodegenerative Diseases What is Progranulin? A neuroprotective protein that has therapeutic potential across several neurodegenerative diseases. It functions as an autocrine neurotrophic factor and increases cell survival signaling pathways. Progran
Slide 21: Alpha-0602: AAV Gene Therapy Program
Alpha-0602: AAV Gene Therapy Program ALPHA-0602 utilizes a well-developed Adeno-Associated Virus (AAV) system to deliver gene constructs to neurons Intent to increase expression of full-length progranulin and GEMs for the treatment of neurological diseases Positive proof of concept results demonstra
Slide 22: ALPHA-1062 Traumatic Brain Injury (TBI) Opportunity
ALPHA-1062 Traumatic Brain Injury (TBI) Opportunity Large, Underserved Better Diagnosis, ALPHA-1062’s TBI Program Market Better Results Active Metabolite Intranasal Formulation Nearly 3M diagnosed in the Historic failures in clinical May reduce neuronal cell All IND-enabling studies USA annually tri
Slide 23: Alpha 1062 Acutely Preserves & Persistently Improves Functional Recovery after TBI
Alpha 1062 Acutely Preserves & Persistently Improves Motor, Sensory, and Cognitive Functional Recovery after TBI As compared to the vehicle control, Alpha 1062: • Statistically significantly improved motor and sensory functional recovery in rats after TBI measured by footfault, adhesive removal and
Slide 24: Executive Team Has Over 50 Drug Approvals And 20 Commercial Launches
Executive Team Has Over 50 Drug Approvals And 20 Commercial Launches $4.1M Michael Mcfadden Cedric O’Gorman, MD Lauren D’Angelo CEO Chief Medical Officer Chief Commercial Officer Jeremy Wright Denis Kay Chief Financial Officer Chief Scientific Officer COPYRIGHT 2021 ALPHA COGNITION, INC. 24
Slide 25: Potential Catalysts & Upcoming Events
Potential Catalysts & Upcoming Events 2022 Top-line results of the ALPHA-1062 pre-clinical study in mTBI (Q1) Top-line results of gene therapy ALPHA-0602 pre-clinical study results (Q1) Top-line results of the ALPHA-1062 pivotal trial in AD (Q2) Begin enrollment of ALPHA-1062 patient tolerability st
Slide 26: Key Investor Considerations
Key Investor Considerations De-risked clinical program with accelerated path to FDA approval: targeted approval in 1H 2023 Large established market; significant patient and physician dissatisfaction with current treatments Differentiated product that addresses areas of high unmet medical need Effici
Slide 27: Glen Akselrod
Glen Akselrod Bristol Investor Relations [email protected] (905) 326-1888 Ext 1 COPYRIGHT 2021 ALPHA COGNITION, INC. 27